MetaShape Pharma Announces Presentations at the American Diabetes Association’s 2026 Scientific Sessions
New preclinical data on MS 001 in combination with semaglutide selected for ADA Late Breaking Poster Session and ePoster Theater RIEHEN, BASEL, SWITZERLAND, April 28, 2026 /EINPresswire.com/ -- MetaShape Pharma AG (“MetaShape”, or “the Company”), a …